Dr. Joseph Schoeman


M.B.B.S. (Pretoria), FRACS Urology, FCS Urology SA Specialist Urological Surgeon,

The Wesley Hospital and St. Andrews War Memorial Hospital, Brisbane; Caboolture Private Hospital, Sunshine Coast, and Mater Private Hospital, Bundaberg

Dr. Joseph (Jo) Schoeman is an experienced and skilled Functional Urologist with a special interest in the management of the enlarged prostate with lower urinary tract symptoms (BPH), prostate cancer and urinary incontinence, specifically the overactive bladder. He is based at The Wesley Hospital, and also practices at St. Andrews War Memorial Hospital, Brisbane; Caboolture Private Hospital, Sunshine Coast; and Mater Private Hospital, Bundaberg.

He has clinical interests in the management of benign prostatic hyperplasia (BPH) also known as enlarged prostate – a common disease affecting older men¹ involving a non-cancerous (benign) enlargement of the prostate gland, and expansion of the surrounding tissues^{2,3} – focusing on minimally invasive surgical therapies (MIST). He also specialises in the management of prostate cancer with robotic-assisted surgical removal, and incontinence in all patients, managed with intravesical BOTOX, and Neuromodulation.







Dr. Schoeman is a member of many prestigious medical organisations, such as RACS, Urology Society of Australia and New Zealand (USANZ), Uro-Gynaecological Society of Australia, International Uro-gynaecological Association, and the Societe International d'Urologie.

He was a founding member of the Pelvic Medicine Centre, dedicated to the management and treatment of urinary incontinence at St Andrews War Memorial Hospital, Brisbane.

He was also part of the first Australian Accredited Robotic Centre of Excellence at the Wesley Hospital, Brisbane. He is among a handful of Urologists to have performed a radical perineal prostatectomy (surgery to remove the entire prostate and some of the tissue around it, including the seminal vesicles) on select patients in Australia.



To coordinate an interview with Dr Joseph Schoeman, please contact:

Kirsten Bruce and Sam Jacobs, VIVA! Communications

M 0401 717 566 | 0422 654 404

T 02 9968 3741 | 1604

E <u>kirstenbruce@vivacommunications.com.au</u>| <u>sam@vivacommunications.com.au</u>|

References

- 1. Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Healthy Longevity. 2022;3(11):e754-e76.
- 2. Franco JVA, Tesolin P, Jung JH. Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures. Prostate Int. 2023;11(1):1-7.
- 3. Benign prostate hyperplasia (BPH): Urology Care Foundation; 2023. Available from: https://www.urologyhealth.org/urology-a-z/b/benign-prostatic-hyperplasia-(bph).